Across TCGA pan-cancer cohorts, TMEM106A mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TMEM106A data layer compared with 21 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TMEM106A mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TMEM106A expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

CCRCC, LSCC, and LUAD are the cancer types where TMEM106A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.257	0.947	.005	35	view →
LSCC	DFS	Median	All	0.767	0.181	.024	2	view →
LUAD	OS	Tertile	II,III,IV	0.816	0.365	.024	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: TMEM106A tumor-vs-normal RNA expression · all TMEM106A data types